Literature DB >> 30807787

Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration.

Yue Wu1, Li Tang2, Gissou Azabdaftari3, Elena Pop4, Gary J Smith4.   

Abstract

Adrenal androgens dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) are potential substrates for intracrine production of testosterone (T) and dihydrotestosterone (DHT), or directly to DHT, by prostate cancer (PCa) cells. Production of DHT from DHEAS and DHEA, and the role of steroid sulfatase (STS), were evaluated ex vivo using fresh human prostate tissue and in vitro using human PCa cell lines. STS was expressed in benign prostate tissue and PCa tissue. DHEAS at a physiological concentration was converted to DHT in prostate tissue and PCa cell lines, which was STS-dependent. DHEAS activation of androgen receptor (AR) and stimulation of PCa cell growth were STS-dependent. DHEA at a physiological concentration was not converted to DHT ex vivo and in vitro, but stimulated in vivo tumor growth of the human PCa cell line, VCaP, in castrated mice. The findings suggest that targeting metabolism of DHEAS and DHEA may enhance androgen deprivation therapy.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adrenal androgen; Androgen; Intracrine androgen metabolism; Metabolism; Prostate cancer; Steroid sulfatase

Mesh:

Substances:

Year:  2019        PMID: 30807787      PMCID: PMC6438375          DOI: 10.1016/j.mce.2019.02.018

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  62 in total

Review 1.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 2.

Authors:  R E Sobel; M D Sadar
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

2.  Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer.

Authors:  Matthew Fankhauser; Yuen Tan; Geoff Macintyre; Izhak Haviv; Matthew K H Hong; Anne Nguyen; John S Pedersen; Anthony J Costello; Christopher M Hovens; Niall M Corcoran
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

3.  A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer.

Authors:  R Charles Coombes; Fatima Cardoso; Nicolas Isambert; Thierry Lesimple; Patrick Soulié; Concepcion Peraire; Veronique Fohanno; Anne Kornowski; Tauhid Ali; Peter Schmid
Journal:  Breast Cancer Res Treat       Date:  2013-06-25       Impact factor: 4.872

Review 4.  Advances in the analytical methodologies: Profiling steroids in familiar pathways-challenging dogmas.

Authors:  Liezl M Bloem; Karl-Heinz Storbeck; Pieter Swart; Therina du Toit; Lindie Schloms; Amanda C Swart
Journal:  J Steroid Biochem Mol Biol       Date:  2015-04-11       Impact factor: 4.292

5.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.

Authors:  K A Klein; R E Reiter; J Redula; H Moradi; X L Zhu; A R Brothman; D J Lamb; M Marcelli; A Belldegrun; O N Witte; C L Sawyers
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440

6.  The antiandrogenic effect of finasteride against a mutant androgen receptor.

Authors:  Yue Wu; Rishi Raj Chhipa; Haitao Zhang; Clement Ip
Journal:  Cancer Biol Ther       Date:  2011-05-15       Impact factor: 4.742

7.  Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.

Authors:  H C Wu; J T Hsieh; M E Gleave; N M Brown; S Pathak; L W Chung
Journal:  Int J Cancer       Date:  1994-05-01       Impact factor: 7.396

Review 8.  A role for the androgen-receptor in clinically localized and advanced prostate cancer.

Authors:  James L Mohler
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

9.  Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.

Authors:  Yue Wu; Alejandro Godoy; Faris Azzouni; John H Wilton; Clement Ip; James L Mohler
Journal:  Prostate       Date:  2013-06-27       Impact factor: 4.104

10.  The activities of 5α-reductase and 17,20-lyase determine the direction through androgen synthesis pathways in patients with 21-hydroxylase deficiency.

Authors:  Clemens Kamrath; Michaela F Hartmann; Thomas Remer; Stefan A Wudy
Journal:  Steroids       Date:  2012-08-23       Impact factor: 2.668

View more
  5 in total

1.  Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.

Authors:  Renjie Jin; Connor Forbes; Nicole L Miller; Douglas Strand; Thomas Case; Justin M Cates; Hye-Young H Kim; Phillip Wages; Ned A Porter; Krystin M Mantione; Sarah Burke; James L Mohler; Robert J Matusik
Journal:  Prostate       Date:  2022-07-12       Impact factor: 4.012

2.  Recapitulation of prostate tissue cell type-specific transcriptomes by an in vivo primary prostate tissue xenograft model.

Authors:  Nelson T Gross; Jianmin Wang; Michael V Fiandalo; Eduardo Cortes Gomez; Anica Watts; Alejandro S Godoy; Gary J Smith; Yue Wu
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240

3.  Components of the human-specific, p53-mediated "kill switch" tumor suppression mechanism are usurped by human tumors, creating the possibility of therapeutic exploitation.

Authors:  Jonathan Nyce
Journal:  Cancer Drug Resist       Date:  2019-12-19

Review 4.  Steroid Sulphatase and Its Inhibitors: Past, Present, and Future.

Authors:  Paul A Foster
Journal:  Molecules       Date:  2021-05-11       Impact factor: 4.411

5.  Differential Associations of SLCO Transporters with Prostate Cancer Aggressiveness between African Americans and European Americans.

Authors:  Li Tang; Qianqian Zhu; Zinian Wang; Clayton M Shanahan; Jeannette T Bensen; Elizabeth T H Fontham; Gary J Smith; Elena A Pop; Gissou Azabdaftari; James L Mohler; Yue Wu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-02-22       Impact factor: 4.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.